MiMedx Group announced it will acquire Sanara MedTech for approximately $350 million in a cash and stock deal, aiming to create a leading regenerative medicine company. The merger will nearly double MiMedx's surgical revenue and expand its product portfolio with Sanara's innovative surgical technologies, including a breakthrough bone fixation device. The combined company expects 2027 revenue to exceed $400 million with over 20% adjusted EBITDA margin, benefiting from $20 million in cost synergies. The deal, approved by both boards, is expected to close by year-end pending shareholder and regulatory approvals.
Avalanche (AVAX) has surged past the $10 mark after breaking out from a consolidation range between $7.00 and $8.20, supported by a sharp increase in trading volume. The price climbed to around $10.27, clearing multiple resistance levels and reclaimi...
Zcash (ZEC) price retreated from a recent high near $1,600 to around $1,443 amid increased selling pressure, signaling a healthy correction after a strong rally. Despite the pullback, technical indicators remain bullish, with ZEC holding above major ...
Avalanche's AVAX price rose 18% due to three key events: New York Life Investment Management launched its first tokenized high-yield bond fund on Avalanche, Paxos added AVAX to its regulated payment services, and a network upgrade on September 22 wil...
Orthocell Ltd has made its first commercial sales of Remplir, a nerve repair product, in Thailand following Thai FDA approval and the appointment of MediTime as its exclusive distributor. This launch opens access to Thailand's estimated $84 million n...
Strategy (MSTR) stock surged 16.39%, closing at $153.92 after heavy trading volume more than doubling its average daily shares. The rise is closely tied to Bitcoin's price, as Strategy holds around 845,000 BTC worth about $69 billion, making Bitcoin'...
